Pesquisar
Neumora Therapeutics Inc
NMRAAdicionar à lista de desejos
1.670USD
+0.050+3.09%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
304.20MValor de mercado
PerdaP/L TTM
Mais detalhes de Neumora Therapeutics Inc Empresa
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Informações de Neumora Therapeutics Inc
Código da empresaNMRA
Nome da EmpresaNeumora Therapeutics Inc
Data de listagemSep 15, 2023
CEOBerns (Paul L)
Número de funcionários110
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 15
Endereço260 Arsenal Place, Suite 1
CidadeWATERTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02472
Telefone18577600900
Sitehttps://neumoratx.com/
Código da empresaNMRA
Data de listagemSep 15, 2023
CEOBerns (Paul L)
Executivos da empresa Neumora Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Ms. Helen Rubinstein
Ms. Helen Rubinstein
IR Contact Officer
IR Contact Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Neumora Therapeutics Inc?
Os cinco principais acionistas de Neumora Therapeutics Inc são: Mr. Paul L. Berns
Quantas instituições possuem ações da Neumora Therapeutics Inc (NMRA)?
Em 2026Q1, 301 instituições possuíam ações da Neumora Therapeutics Inc, com valor de mercado aproximado de 106.55M, representando 57.52% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -16535931.00.